The findings suggested that NOP2 may serve as a novel biomarker and therapeutic target for HCC and demonstrated that the MAZ/NOP2/c-Myc signaling pathway may be a novel mechanism for HCC proliferation and metastasis. This evidence concerns the gene NOP2 and hepatocellular carcinoma.